“Dose-Modified Lenalidomide Induces Sustained Hematological Response in Patients With Intermediate to High Risk Myelodysplasia”. Mediterranean Journal of Hematology and Infectious Diseases 2, no. 2 (May 31, 2010): e2010012. Accessed May 21, 2026. https://www.mjhid.org/mjhid/article/view/2010.012.